Citizens Financial Group Inc. RI Buys 3,931 Shares of Boston Scientific Co. (NYSE:BSX)

Citizens Financial Group Inc. RI boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 78.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,970 shares of the medical equipment provider’s stock after buying an additional 3,931 shares during the period. Citizens Financial Group Inc. RI’s holdings in Boston Scientific were worth $801,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in BSX. Impax Asset Management Group plc boosted its stake in Boston Scientific by 17.5% during the third quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock valued at $457,138,000 after buying an additional 815,403 shares during the period. Mesirow Financial Investment Management Inc. bought a new stake in Boston Scientific during the third quarter valued at $222,000. Sigma Planning Corp lifted its stake in Boston Scientific by 5.2% during the third quarter. Sigma Planning Corp now owns 7,900 shares of the medical equipment provider’s stock worth $662,000 after purchasing an additional 389 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in Boston Scientific by 62.5% during the third quarter. Venturi Wealth Management LLC now owns 1,799 shares of the medical equipment provider’s stock worth $151,000 after purchasing an additional 692 shares during the last quarter. Finally, Harbour Investments Inc. lifted its stake in Boston Scientific by 11.5% during the third quarter. Harbour Investments Inc. now owns 2,817 shares of the medical equipment provider’s stock worth $236,000 after purchasing an additional 291 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $96.42 on Thursday. The stock’s 50 day simple moving average is $100.80 and its two-hundred day simple moving average is $91.52. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a market cap of $142.29 billion, a price-to-earnings ratio of 77.14, a PEG ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares of the company’s stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 137,302 shares of company stock valued at $14,319,269 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on BSX shares. JPMorgan Chase & Co. lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Barclays lifted their price target on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Morgan Stanley lifted their price target on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Friday, January 10th. Finally, Canaccord Genuity Group lifted their price objective on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.